251 related articles for article (PubMed ID: 26395769)
1. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study.
Polard E; Nowak E; Happe A; Biraben A; Oger E;
Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1161-9. PubMed ID: 26395769
[TBL] [Abstract][Full Text] [Related]
2. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Contin M; Alberghini L; Candela C; Benini G; Riva R
Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
[TBL] [Abstract][Full Text] [Related]
3. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK
Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of generic versus brand-name antiepileptic medications.
Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
[TBL] [Abstract][Full Text] [Related]
5. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
6. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
Rascati KL; Richards KM; Johnsrud MT; Mann TA
Pharmacotherapy; 2009 Jul; 29(7):769-74. PubMed ID: 19558250
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
8. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
[TBL] [Abstract][Full Text] [Related]
9. Brand name to generic substitution of levetiracetam in patients with epilepsy.
Gha-Hyun L; Dae SJ
Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217
[TBL] [Abstract][Full Text] [Related]
10. Refilling and switching of antiepileptic drugs and seizure-related events.
Gagne JJ; Avorn J; Shrank WH; Schneeweiss S
Clin Pharmacol Ther; 2010 Sep; 88(3):347-53. PubMed ID: 20631693
[TBL] [Abstract][Full Text] [Related]
11. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
Holtkamp M; Theodore WH
Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic equivalency of generic antiepileptic drugs: results of a survey.
Wilner AN
Epilepsy Behav; 2004 Dec; 5(6):995-8. PubMed ID: 15582850
[TBL] [Abstract][Full Text] [Related]
13. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
14. The use of generic medication in epilepsy: a review of potential issues and challenges.
Van Paesschen W; Hauman H; Lagae L
Eur J Paediatr Neurol; 2009 Mar; 13(2):87-92. PubMed ID: 18790656
[TBL] [Abstract][Full Text] [Related]
15. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
Hartung DM; Middleton L; Svoboda L; McGregor JC
CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
[TBL] [Abstract][Full Text] [Related]
16. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
Kesselheim AS; Stedman MR; Bubrick EJ; Gagne JJ; Misono AS; Lee JL; Brookhart MA; Avorn J; Shrank WH
Drugs; 2010 Mar; 70(5):605-21. PubMed ID: 20329806
[TBL] [Abstract][Full Text] [Related]
17. The risks and costs of multiple-generic substitution of topiramate.
Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
[TBL] [Abstract][Full Text] [Related]
18. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
[TBL] [Abstract][Full Text] [Related]
19. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
Rathe JØ
Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes associated with brand-to-generic phenytoin interchange.
Kinikar SA; Delate T; Menaker-Wiener CM; Bentley WH
Ann Pharmacother; 2012 May; 46(5):650-8. PubMed ID: 22550275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]